Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children

Article Abstract:

An investigation of the pharmacokinetics of increased-dose lopinavir and ritonavir with normal-dose efavirenz in HIV-1-infected children is presented. The results revealed that the increased dose of 300/75 mg/m(super 2) twice-daily lopinavir and ritonavir compensates for the enzyme-inducing effect of efavirenz in HIV-infected children.

Author: Burger, David M., Bergshoeff, Alina S., Fraaij, Pieter L., Ndagijimana, Jennifer, Verweel, Gwenda, Groot, Ronald De, Hartwig, Nico G., Niehues, Tim
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
Ritonavir, Drug therapy, HIV infection in children, Pediatric HIV infections, Dosage and administration

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Pharmacokinetics of indinavir/ritonavir (800/100mg) in combination with efavirenz ({600mg) in HIV-1-infected subjects

Article Abstract:

Efavirenz (600mg) is added to indinavir/ritonavir (800/100mg) results in significant decreases in indinavir levels in healthy volunteers. The combination of indinavir/ritonavir (800/100mg) bid and efavirenz at 600mg results in adequate minimum concentrations of both indinavir and efavirenz for treating native patients.

Author: Cooper, David A., Burger, David M., Aarnoutse, Rob E., Phanuphak, Praphan, Boyd, Mark A., Ruxrungtham, Kiat, Stek, Michael, Jr, Heeswijk, Rolf P. G. van, Lange, Joep M. A.
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2003
Indinavir, Patients, Pharmacokinetics

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA

Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy

Article Abstract:

An interim analysis based on the data from the first 400 patients to assess possible differences in plasma HIV-1RNA (pVL) decline between the treatment groups is presented. A similar rate of initial decline of pVL for nevirapine (NVP), efavirenz (EFV), and NVP + EFV after adjusting for baseline pVL and region is shown.

Author: Montaner, Julio S. G., Hall, David B., Badaro, Roberto, Lange, Joep M. A., Leth, Frank van, Huisamen, Casper B., Wit, Ferdinand W. N. M., Vandercam, Bernard, Wet, Joss de
Publisher: Lippincott Williams & Wilkins, WK Health
Publication Name: Journal of Acquired Immune Deficiency Syndromes (1999)
Subject: Health
ISSN: 1525-4135
Year: 2005
RNA, Nevirapine, Efavirenz (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Research
Similar abstracts:
  • Abstracts: Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: Results from ACTG 384
  • Abstracts: The Supreme Court and the purposes of medicine. Doctors and drug companies- scrutinizing influential relationships
  • Abstracts: Educational needs of nurses working in nursing homes. 'The NHS is treating its job applicants with disrespect'
  • Abstracts: Manticipation. Galculus: definition: the complicated numerical formulas women use to plot their dating moves. Bland date
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.